LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
OMER
Omeros Corporation
There isn't enough reported data to score OMER yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
OMER Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Unavailable |
OMER's profitability is currently healthy. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over OMER in the historical PE scenario, which offers more potential upside but is not a forecast.
OMER PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 1x | $1.76 | -90% |
| Fair | 5.3x | $9.22 | -49% |
| Forward | 5.5x | $17.99 | — |
| Expensive | 10x | $17.82 | -1% |
| Current | 10x | $17.99 | — |
Historical ranges are pointers, not guarantees.
OMER's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
OMER Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Returning to profit | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect OMER to return to profit, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over OMER on earnings, with more consistent year-over-year improvement.
OMER Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.25 | +88% |
| Q2 2026 | $1.73 | +$3.84 |
| Q1 2026 | $1.15 | +$3.80 |
| Q4 2025 | -$0.05 | +$2.65 |
| Q3 2025 | -$2.02 | +$0.28 |
| Q2 2025 | -$2.11 | +$0.23 |
| Q1 2025 | -$2.65 | -$0.69 |
| Q4 2024 | -$2.70 | -$0.83 |
| Q3 2024 | -$2.30 | -797% |
OMER has returned to profit: it earned $1.73 per share over the past year, after losing money the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the stronger quarterly revenue trend. Revenue is up 39% for LLY versus up 35% for OMER.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over OMER on profitability, with a higher operating margin.
OMER Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2021 | $30M | +15% |
| Q2 2021 | $28.8M | +113% |
| Q1 2021 | $21.1M | -11% |
| Q4 2020 | $10.6M | -68% |
| Q3 2020 | $26.1M | -13% |
OMER's revenue is growing: $29M last quarter, up 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 0.3% | N/A |
| Q1 2026 | -176% | N/A |
| Q3 2021 | -61% | +37 points |
| Q2 2021 | -83% | +121 points |
| Q1 2021 | -145% | -45 points |
| Q4 2020 | -318% | -247 points |
| Q3 2020 | -97% | -60 points |
| Q2 2020 | -205% | N/A |
OMER's operating margin was 0.3% last quarter, up 146 points from the same quarter a year ago, near the top of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over OMER on cash generation, producing positive trailing cash flow while its opponent burns cash.
OMER Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $4.1M | +$26.1M |
| Q1 2026 | -$14.5M | +$21.4M |
| Q4 2025 | -$39.8M | -$10.8M |
| Q3 2025 | -$18.5M | +$13.6M |
| Q2 2025 | -$22M | +$24.1M |
| Q1 2025 | -$35.9M | +$6M |
| Q4 2024 | -$29M | +$5.9M |
| Q3 2024 | -$32.1M | +$621K |
OMER has burned cash in almost every quarter: −$69M over the past year, against −$119M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over OMER on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
OMER Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -491K shares |
| 1 year | +53% | +31M shares |
| 3 years | +43% | +26.8M shares |
| 5 years | +44% | +27.3M shares |
| Available history | +82% | +40.3M shares |
OMER has 90M diluted shares, up 53% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $5.7M |
| Q1 2026 | $4.2M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
OMER spent $10M buying back its own shares over the past year, after none the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
OMER Net Leverage
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
OMER Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.2 | Neutral |
| Stochastic | 62.7 | Neutral |
OMER's weekly RSI is 57 (neutral) and its Stochastic is 63 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
OMER PE vs Healthcare Sector
| Metric | OMER | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 85 | 29 | 56 pts above |
OMER has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over OMER on trend strength, trading above more of its moving averages.
OMER Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.1 | 0.5% below |
| 20 week MA | $16.0 | 13% above |
| 50 week MA | $13.4 | 34% above |
| 100 week MA | $9.89 | 82% above |
| 200 week MA | $7.06 | 155% above |
OMER's trend is up, with a small recent dip: it's below only its 8-week average, and 155% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over OMER on returns for 2026, with the stronger performance.
OMER Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.0 | $14.9 | -0.7% |
| 2021 | $14.9 | $7.64 | -49% |
| 2022 | $7.64 | $2.54 | -67% |
| 2023 | $2.54 | $3.27 | +29% |
| 2024 | $3.27 | $11.7 | +257% |
| 2025 | $11.7 | $15.7 | +35% |
| 2026 YTD | $15.7 | $18.0 | +15% |
OMER's yearly returns have swung widely, from +257% in 2024 to −67% in 2022. It's up 15% so far in 2026.